thill@rapidappl...
The following refers to: 3DPX-013444
The FDA has authorized production of protective face shields outside of the normal clearance pathway during the COVID-19 pandemic, based on Part 5, section D of the “Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency Guidance for Industry and Food and Drug Administration Staff." This face shield has undergone review in a clinical setting and is recommended when fabricated as instructed.
This is a Rapid Application Group design optimized for selective laser sintering (SLS). This will allow those with Selective Laser Sintering or MJP assets to have a clinical tested design for production. This was designed with a local consortium that Rapid Application Group lead with local healthcare professionals.
Features:
Bill of Materials (BOM):
Assembly Instructions:
This design was a collaboration of multiple players: